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 Contributions of peroxisome proliferator-activated 
receptor  β / δ to skin health and disease 
 Abstract:  Among the three peroxisome proliferator-
activated receptor (PPAR) transcription factors, PPAR β / δ is 
the isotype with the broadest expression pattern. In fact, the 
expression of PPAR β / δ is ubiquitous, albeit at levels that are 
tightly regulated. Herein, we reviewed its multiple functions 
in skin health and disease. PPAR β / δ has pro-differentiating 
effects in keratinocytes, regulates sebocyte differentiation, 
and promotes hair follicle growth in healthy skin. Further-
more, we reviewed novel insights into the roles of PPAR β / δ 
in skin wound healing, especially in inhibiting apoptosis 
and in modulating keratinocyte proliferation and migra-
tion. Therefore, PPAR β / δ represents a research target for the 
understanding and treatment of inflammatory skin diseases, 
such as psoriasis and acne vulgaris. In addition, PPAR β / δ 
is a tumor growth modifier. Epidemiological studies have 
established that tumor progression may be exacerbated by 
chronic low-grade inflammation, a condition promoting the 
production of the lipids that act as modulators of PPAR β / δ 
activity. The action of PPAR β / δ in skin cancer is ambivalent, 
which might be explained by this receptor ’ s putative highly 
context-specific behavior, which depends on a combination 
of factors ranging from receptor expression levels to co-reg-
ulator distribution, diversity and activity of the ligands pro-
duced, and other tissue-specific conditions. Given its diverse 
and crucial roles in many tissues and organs, PPAR β / δ will 
remain a major focus of future research. 
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 Introduction 
 The skin is the largest organ of the body with respect to 
weight and surface area. The outer layers of cells in the 
skin compose the epidermis, which together with the 
dermis forms the cutis. In the latest stages of fetal devel-
opment, the epidermis develops into a fully stratified 
and differentiated epithelium that undergoes continu-
ous renewal after birth. In fact, the basal layer of this 
stratified tissue contains undifferentiated proliferating 
keratinocytes that undergo a differentiation program as 
they migrate from the basal to the uppermost layer of 
the epidermis. The basal layer is the source of skin cells 
throughout life, which are generated through asymmetri-
cal division  (1, 2) . This cell layer is maintained through 
several autocrine and paracrine acting factors, which are 
important for epidermal homeostasis  (3 – 5) . The vectorial 
differentiation program of keratinocytes comprises the 
processing of lipids [sphingolipids, free fatty acids (FAs), 
and cholesterol] and the sequential expression of struc-
tural proteins (keratins, involucrin, loricrin, and filag-
grin), which are each essential to the protective function 
of the epidermis. In fact, the outermost layer of the epi-
dermis, the stratum corneum, consists of a layer of cross-
linked proteins and lipids and dead keratinocytes (cor-
neocytes), which form an efficient barrier against water 
loss, microorganism invasion, mechanical damage, and 
chemical poisoning. The stratum corneum is also where 
desquamation, the natural process by which dead outer 
skin cells are sloughed away and replaced, occurs  (6) . Epi-
dermal homeostasis and the integrity of the barrier func-
tion depend on a well-tuned coordination of keratinocyte 
proliferation, differentiation, positioning in the tissue, 
and apoptosis. 
 As in other organs, lipid signaling contributes to 
skin health and disease. The nuclear receptors called 
 peroxisome proliferator-activated receptors (PPARs) 
are key mediators of lipid signaling. They sense diverse 
lipophilic molecules that act as ligands and thereby link 
fluctuations in the levels and distribution of FAs, eicos-
anoids, and some phospholipids to differential gene 
expression  (7, 8) . There are three related PPAR isotypes 
that compose a small subfamily of nuclear receptors: 
PPAR α (NR1C1), PPAR β / δ (NR1C2), and PPAR γ (NR1C3) 
 (9) . The transcriptional activity of all three of them is 
mediated by PPAR:retinoid X receptor heterodimers that 
bind to specific DNA sequence elements termed peroxi-
some proliferator response elements. By doing so, they 
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regulate the expression of genes implicated in several 
important processes, such as lipid and carbohydrate 
metabolism, tissue repair, vascular biology, and sexual 
dimorphism, as well as in more general basic cellular 
processes, such as proliferation, differentiation, and 
migration  (10, 11) . 
 The expression patterns of PPAR α , PPAR β / δ , and 
PPAR γ are well described  (10, 12, 13) . Although present-
ing some specificity, they are also overlapping, with 
distinct expression levels. PPAR α , which has been 
well described in FA catabolism, is highly expressed in 
brown adipose tissue, heart, liver, kidney, and intes-
tines, whereas PPAR β / δ is relatively abundant in the 
brain, skeletal muscle, gut, placenta, and skin. The third 
isotype, PPAR γ , is expressed as two isoforms,  γ 1 and  γ 2. 
PPAR γ 1 is 28 and 30 amino acids shorter at its N-termi-
nus than PPAR γ 2 in rodents and humans, respectively. 
PPAR γ 1 also has a broader expression pattern, which 
includes immune cells, brain, gut, and endothelial cells, 
whereas PPAR γ 2 is found mainly in adipose tissues. This 
list is not exhaustive; a more detailed description of 
PPAR expression can be found in previous articles  (10, 
12 – 14) . 
 In recent years, PPARs (and especially PPAR β / δ ) have 
emerged as having multifaceted key roles in skin health 
and disease (Figure  1 ). Characterized natural PPAR β / δ 
ligands are unsaturated FAs, saturated FAs (weak), pros-
tacyclin, 4-hydroxy-2-nonenal, 4-hydroxydodeca-(2 E ,6 Z )-
dienal, and very low-density lipoprotein components  (15) . 
The present review summarizes our current knowledge of 
PPAR β / δ functions in rodent and human skin, including 
embryonic development, the maintenance of adult skin 
and skin appendages, and normal skin repair. We also 
discuss the implication of PPAR β / δ in skin pathologies, 
such as hyperproliferative and inflammatory diseases, 
and cancer. 
 Skin development: cell differentia-
tion, epidermis, and appendages 
 The three PPAR isotypes are expressed in rodent and 
human skin. Cell culture and  in vivo approaches have 
demonstrated that PPAR β / δ has pro-differentiating effects 
in keratinocytes in normal and inflammatory conditions, 
regulates hair follicle growth, and promotes sebocyte 
differentiation. 
 In keratinocytes from adult human epidermis, PPAR β / δ 
is constitutively expressed and is present throughout all epi-
dermal layers  (16 – 18) . In contrast, in the interfollicular epi-
dermis of rodents, PPAR β / δ is expressed at relatively high 
levels during development and much less in the adult epi-
dermis  (19) . In mouse keratinocytes, PPAR β / δ expression 
can be down-regulated by C/EBP α and C/EBP β through 
a mechanism that requires both the binding of C/EBP to 
the promoter of the PPAR β / δ gene and histone deacetyla-
tion. We propose that such interplay between PPAR β / δ and 
C/EBP transcription factors is crucial to the molecular 
control of the balance between differentiation and prolif-
eration  (20) . Furthermore, keratinocyte fatty acid binding 
protein (K-FABP) is essential to the ability of PPAR β / δ to 
properly induce keratinocyte differentiation. Hence, the tis-
sue-specific expression of particular FABPs may support the 
tissue-specific functions of PPARs, which raises the intrigu-
ing possibility that the same K-FABP – PPAR β / δ pair plays 
a similar role in mediating the differentiation of other cell 
types in which both factors are expressed concomitantly 
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 Figure 1   Functions of PPARs in the epidermis and epidermal appendages. 
 This schematic outlines the skin structures and functions of PPARs in the interfollicular epidermis, sebocytes, and hair follicles. Observa-
tions obtained after activation of PPARs by their specific ligands in three skin structures are summarized (see text for references). 
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 (21) . The pro-differentiating action of ligand-activated 
PPAR β / δ is keratinocyte-autonomous and mediated by an 
indirect mechanism that involves the transcriptional regu-
lation of adipocytokine angiopoietin-like 4 (ANGPTL4) and 
the subsequent activation of protein kinase C and activator 
protein 1 (AP-1) transcription factors  (22) . 
 Hair follicle morphogenesis depends on a strictly con-
trolled balance between keratinocyte proliferation, dif-
ferentiation, and apoptosis. PPAR β / δ is expressed in the 
hair follicles of both fetal and adult skin. Furthermore, 
follicle morphogenesis involves complex bidirectional 
interactions between the keratinocytes and the underly-
ing mesenchyme. These interactions involve hepatocyte 
growth factor (HGF), which is produced by dermal papilla 
cells during early hair follicle development. HGF stimu-
lates cyclooxygenase-2 (COX-2) expression in keratino-
cytes, which results in the activation of PPAR β / δ and the 
subsequent stimulation of the protein kinase B α (PKB α )/
Akt1 pathway at a specific stage of hair follicle develop-
ment. However, in contrast to inflammatory cytokines that 
regulate both PPAR β / δ expression and activation, HGF is 
implicated only in PPAR β / δ activation. Interestingly, HGF 
is a versatile modulator of cell proliferation, migration, 
differentiation, and apoptosis. It has been implicated in 
mesenchyme-epithelium interactions in several tissues 
and has been attributed functions in the morphogenesis 
of other ectodermal structures, such as teeth and feathers, 
which may therefore also require PPAR β / δ activity  (23) . 
 In brief, activation of PPAR β / δ by COX-2-derived 
ligands protects hair peg keratinocytes against apoptosis, 
promoting normal hair follicle development  (24) . 
 Each PPAR isotype is expressed in the basal layer of 
the sebaceous gland, and ligand activation of each isotype 
increases lipogenesis  (25) . The gland comprises sebocytes 
that are epithelial cells, which accumulate neutral fat 
droplets during terminal differentiation. Sebocyte lysis 
releases lipids/sebum into the hair follicle canal, through 
which they reach the surface of the skin where they prevent 
drying of the skin and hair  (26) . Interestingly, PPAR β / δ 
seems to be important in the late stages of sebocyte dif-
ferentiation  (27) , in contrast to its implication in the early 
phase of adipocyte differentiation in adipose tissues  (28) . 
The meaning of this stage-specific effect on the differentia-
tion of two lipogenic cell types remains to be unveiled. 
 Skin lipid metabolism 
 As mentioned above, the permeability barrier resides in 
the stratum corneum and comprises lamellar membranes 
enriched with extracellular neutral lipids surrounding the 
corneocytes  (29, 30) . These extracellular lipids differ from 
the lipids that constitute most biological membranes. 
Their total lipid mass comprises approximately 25 % 
cholesterol, 50 % ceramides, and 15 % free FAs  (31) . Mice 
devoid of PPAR β / δ displayed delayed recovery of the per-
meability barrier, suggesting that this PPAR isotype has a 
physiologic function in permeability barrier homeostasis. 
This delay in barrier recovery was most likely due to the 
decreased synthesis and secretion of lamellar bodies, as 
well as reduced numbers of extracellular lamellar mem-
branes in the stratum corneum  (32) . 
 Treatment of both cultured human keratinocytes 
and mouse epidermis with a selective PPAR β / δ ligand 
(GW1514) increased the accumulation of lipids that were 
predominantly triglycerides, but did not stimulate the 
conversion of keratinocytes to sebocytes or adipocytes. 
It is not yet clear why lipid accumulation is increased in 
these cultured keratinocytes or whether this  in vitro obser-
vation has functional significance  in vivo  (33) . 
 Skin wound healing 
 The formation of a new epithelium after a skin injury is 
part of a healing process that is often lifesaving. The 
initial stage of this process is an immediate inflamma-
tory response to the injury. Next, keratinocytes migrate 
and proliferate to cover the wound bed in the  sensu  stricto 
reepithelialization event. The proliferation of fibroblasts 
from the dermis also contributes to the healing process, 
as does the production of novel blood vessels that irri-
gate the repaired skin. In rodents, PPAR β / δ expression 
is extremely low in the interfollicular adult epidermis, 
but is strongly reactivated and remains relatively high in 
keratinocytes at the edges of wounds as long as the entire 
repair process has not been completed  (19) . The injury-
associated  stimulation of PPAR β / δ is mediated by the acti-
vation of the stress-associated protein kinase pathway by 
inflammatory cytokines that are released after the injury, 
such as tumor necrosis factor - α (TNF- α ) (Figure  2 )  (34) . 
Concomitantly, the production of an endogenous ligand 
(or multiple ligands) is induced, which is a prerequisite 
for activation of the receptor in the keratinocytes  (34) . 
The expression of PPAR β / δ is maximal during the inflam-
matory phase and is then progressively reduced during 
reepithelialization to finally reach levels observed in the 
unwounded skin, once cicatrization has been achieved. 
The down-regulation of PPAR β / δ depends on the inhi-
bition of AP-1 binding to the PPAR β / δ promoter, which 
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 Figure 2   Roles of PPAR β / δ in skin wound healing. 
 The expression of the  Ppar β / δ gene is stimulated by the AP-1 transcription factor complex, which is activated by the stress-associated 
protein kinase pathway triggered by pro-inflammatory cytokines such as TNF- α . TNF- α also induces the production of PPAR β / δ ligands in 
the injured epithelium. Ligands can also be produced during hair follicle development by COX-2-mediated HGF signaling. Activated 
PPAR β / δ down-regulates  Pten expression and stimulates the genes that encode integrin-linked kinase (ILK) and 3-phosphoinositide-
dependent kinase-1 (PDK1). The latter results in activation through the phosphorylation of PKB α /Akt1, which increases the inhibitory 
phosphorylation of BAD (BCL2-associated agonist of cell death), FKHR (forkhead transcription factor Foxo1), and GSK-3 β (glycogen synthase 
kinase 3 β ), causing reduced apoptosis and increased gene expression and integrin recycling. As epithelialization proceeds, TNF- α -induced 
 Ppar β / δ expression is progressively repressed by Smad3/Smad4 complex-mediated TGF β 1 signaling, which inhibits AP-1 binding to the 
 Ppar β / δ promoter. Increased levels of PIP3 (phosphatidylinositol 3,4,5-trisphosphate) and PDK1 affect the cytoskeleton, which is impli-
cated in directional sensing and cell migration. 
is controlled by transforming growth factor  β 1 (TGF β 1) 
 (35) . The completion of skin repair is delayed by 2 – 3 days 
in PPAR β / δ -deficient mice  (19) , which underscores the 
importance of this transcriptional regulator in wound 
healing. In fact, PPAR β / δ activates the phosphoinositide 
3-kinase (PI3K)/PKB α /Akt1 (PI3K/PKB α /Akt1) pathway, 
which promotes keratinocyte survival at the wound edges 
 (24) . Furthermore, it favors keratinocyte adhesion and 
migration, which promotes reepithelialization  (19, 36) 
(Figure 2). 
 To understand the functional interaction between 
PPAR β / δ and TGF β 1, topical application of recombinant 
TGF β 1 (TGF β 1 pathway gain of function) and Smad3 
(mothers against decapentaplegic homolog 3) deficiency 
(TGF β 1 pathway loss of function) were used  (37) . Manip-
ulating TGF β 1 activity in the epidermis of the wounds 
induced prolonged PPAR β / δ expression and activity, 
which resulted in accelerated wound closure. This result 
suggested that PPAR β / δ expression and activity corre-
late with healing efficiency. Such knowledge about how 
TGF β 1 regulates PPAR β / δ during wound healing may help 
improve treatments for chronic wound disorders. 
 Moreover, gene expression profiling in wild type and 
PPAR β / δ -deficient primary keratinocyte cultures revealed 
similar amounts of genes stimulated or repressed by 
PPAR β / δ . Comparative analysis of expressed genes con-
firmed PPAR β / δ functions in cell proliferation, differenti-
ation, migration, and adhesion  (11) . Of particular interest, 
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the most deregulated genes were genes previously impli-
cated in cell proliferation, tumor growth, and angiogen-
esis  (38 – 40) . For instance, three of these genes, Akt1, 
Cxcl12, and Src, regulate the PI3K and mitogen-activated 
protein kinase (MAPK) pathways, both of which have been 
implicated in skin wound healing. In brief, PPAR β / δ defi-
ciency in keratinocytes affected gene expression, which 
may explain the phenotypic changes observed during 
skin wound healing in PPAR β / δ -deficient mice  (11) . 
 The regeneration of the epithelium to close a wound 
depends on a contribution from the underlying dermal 
tissue, particularly fibroblasts and fibroblast-like cells, 
called fibrocytes, derived from the bone marrow (Figure  3 ) 
 (41, 42) . Regulation of the crosstalk between keratinocytes 
and fibroblasts is central to preventing either insufficient 
or excess wound repair. Notably, keratinocyte prolif-
eration after an injury must be fine-tuned for reepitheli-
alization  (43) . Interestingly, PPAR β / δ deficiency caused 
epidermal hyperproliferation in early wound repair, upon 
hair plucking, or in response to a topical challenge with 
the phorbol ester 12- O -tetradecanoylphorbol-13-acetate 
(TPA)  (19, 44) . During wound healing, this keratino-
cyte proliferation is under the control of fibroblasts that 
produce mitogenic factors whose genes are under the 
control of AP-1, which is itself under the upstream regula-
tion of the interleukin 1 (IL-1) released by keratinocytes at 
the site of injury (Figure 3). In parallel, activated PPAR β / δ 
in fibroblasts increases the production of the secretory IL-1 
receptor antagonist (sIL-1Ra), resulting in the autocrine 
down-regulation of IL-1 signaling. As a consequence, the 
production of secreted mitogenic factors by the fibroblasts 
is reduced and the proliferation of keratinocytes is down-
regulated  (43) . Together, these findings revealed a novel 
paracrine effect of PPAR β / δ on epithelial cell growth, 
which might also operate in other organs in addition to 
skin. Thus, PPAR β / δ controls keratinocyte differentiation, 
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 Figure 3   Non-cell-autonomous control of keratinocytes by PPAR β / δ . 
 Organotypic cultures [OTCs;  (79) ; see scheme] with primary human keratinocytes and fibroblasts were grown with control or PPAR β / δ 
knockdown keratinocytes (kWild type vs. kPPAR β / δ kd) and fibroblasts (fWild type vs. fPPAR β / δ kd). kPPAR β / δ kd presented increased 
apoptosis, whereas fPPAR β / δ kd potentiated keratinocyte proliferation. OTC with both kPPAR β / δ kd and fPPAR β / δ kd exhibited increased 
keratinocyte proliferation and apoptosis  (43) . Keratinocyte proliferation is regulated by a nonautonomous paracrine mechanism. IL-1 
produced by keratinocytes activates c-Jun through IL-1 receptor type 1 (IL-R1) and transforming growth factor  β -activated kinase 1 (TAK1) 
in dermal fibroblasts. c-Jun is an obligate partner of the AP-1 transcription complex, which stimulates the expression of mitogenic factors 
[keratinocyte growth factor (KGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-6, IL-8, IL-10] secreted by the fibroblasts. 
In these cells, PPAR β / δ attenuates IL-1 signaling through the stimulation of sIL-1Ra production; the gene that encodes sIL-1Rra is a direct 
PPAR β / δ target. sIL-1Ra has little affinity for IL-1R2, which is highly expressed in keratinocytes. However, it binds with high affinity to IL-1R1 
expressed by the fibroblasts. Therefore, sIL-1Ra acts as an autocrine antagonist of IL-1 signaling in fibroblasts. The binding of sIL-1Ra to 
IL-1R1 down-regulates IL-1-mediated signaling events and, consequently, the production of several AP-1-mediated mitogenic factors. This 
mechanism leads to reduced keratinocyte proliferation. Therefore, the absence of PPAR β / δ in fibroblasts results in increased keratinocyte 
proliferation  (43) . 
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survival, and migration, as well as keratinocyte prolifera-
tion by cell-autonomous and nonautonomous pathways. 
 Skin diseases 
 Psoriasis 
 Psoriasis is an inflammatory skin disorder in which epi-
dermal hyperproliferation and abnormal keratinocyte dif-
ferentiation are major characteristics. It affects 1 – 2 % of the 
population in the USA and is often debilitating. PPAR β / δ 
is increased in psoriatic areas, most likely through inflam-
matory signals as previously described after a skin injury 
 (45) . A transgenic murine model allowing PPAR β / δ acti-
vation in the epidermis sustained an inflammatory skin 
disease similar to psoriasis, with keratinocyte hyperprolif-
eration, dendritic cell accumulation, and endothelial acti-
vation  (45) . This response required the activation of the 
Th17 subset of T cells, known to be central to psoriasis. Key 
transcriptional programs of psoriasis, such as cholesterol 
synthesis and IL-1-related signaling, were replicated in 
this model, suggesting that PPAR β / δ might regulate these 
changes in psoriasis. Furthermore, phosphorylation of 
signal transducer and activator of transcription 3 (STAT3) 
was enhanced by PPAR β / δ , whereas inhibition of STAT3 
phosphorylation blocked disease development, implicat-
ing PPAR β / δ in this process  (45) . Interestingly, PPAR β / δ 
was also expressed in activated human T cells isolated 
from psoriatic skin lesions, where it is induced by stimula-
tion with type 1 interferon (IFN). This study suggested that 
the induction of PPAR β / δ by type 1 IFN contributes to the 
prolongation of activated T cells in psoriasis-affected skin 
 (46) . Using the same murine model as above, it was shown 
that three selective PPAR β / δ antagonists formulated for 
topical application to the skin demonstrated efficacy in 
reducing psoriasis-like changes triggered by PPAR β / δ acti-
vation. One of these compounds, an irreversible PPAR β / δ 
antagonist (GSK3787), retained efficacy when applied top-
ically only three times per week. Collectively, these obser-
vations suggested the clinical usefulness of topical inhibi-
tion of PPAR β / δ to treat psoriasis, which deserves further 
exploration  (47) . In this experimental model of psoriasis 
triggered by PPAR β / δ overexpression, one can argue that 
inhibiting PPAR β / δ logically suppresses the origin of the 
disease. Thus far, PPAR β / δ antagonists have not been 
evaluated on psoriasis models not induced by experimen-
tal PPAR β / δ overexpression, and antipsoriasis drugs have 
not been applied to the PPAR β / δ -induced disease model. 
In contrast to these encouraging results obtained with 
PPAR β / δ antagonists, a pilot study with psoriatic patients 
showed that the PPAR β / δ agonist tetradecylthioacetic 
acid did not exhibit beneficial effects when topically 
applied on plaque psoriasis  (48) . This finding comes as no 
surprise, given the rather psoriasis-promoting character-
istics of PPAR β / δ described above. 
 Atopic dermatitis 
 Atopic dermatitis (AD) is an inflammatory, chronically 
relapsing, noncontagious, and pruritic dermatosis that is 
linked to alterations of the stratum corneum  (49, 50) . Little 
is known about the putative link between PPAR β / δ and 
AD. In the oxazolone-induced AD-like model in hairless 
mice, topical application of a PPAR β / δ activator (GW0742) 
reversed clinical dermatosis, improved barrier function, 
and increased stratum corneum hydration. These results 
suggest that topical applications of certain activators/
ligands of PPAR β / δ may be worth testing as AD treatment 
in human subjects  (50) . Thus, in contrast to psoriasis, for 
which PPAR β / δ antagonists were beneficial in experimen-
tal models, AD treatment might benefit from PPAR β / δ 
agonists. However, it is important to note that there are 
no human data so far and the data discussed above are 
from an experimental mouse model that shows only a few 
similarities with human AD. 
 Acne 
 Acne is a common skin condition characterized by spots 
that range from mild to inflamed pus-filled pustules and 
cysts. When long-lasting, it can lead to scarring. Sebum 
secretion can be considered the major factor responsible 
for acne, even if seborrhoea  per se is not a sufficient con-
dition for its development. Current studies concentrate on 
the factors that regulate sebum composition and secretion. 
Differences in the type, amount, and arrangement of FAs 
in the sebum lipids have been reported in acne patients. 
Unsurprisingly, a number of lipid mediators that have been 
shown to be PPAR ligands impact sebocyte lipid synthesis 
and metabolism  (51) . In fact, increased sebum levels com-
bined with follicular hyperkeratinization are hallmarks of 
acne vulgaris, and PPAR β / δ was found overexpressed in 
inflammatory and non-inflammatory acne vulgaris  (52) . 
Given that the suppression of sebum secretion correlates 
with reduced acne, the manipulation of PPAR activity in 
this condition is worthy of additional exploration. 
 Among PPAR activators, the PPAR β / δ ligand L-165.041, 
compared with PPAR α and PPAR γ ligands, was the most 
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efficient at inhibiting basal and staurosporine-induced 
apoptosis in the human sebocyte cell line SZ95  in vitro . 
L-165.041 activated PKB/Akt and p44/42 MAPK, two 
kinases involved in antiapoptosis activity and prolifera-
tion, respectively. The inhibition of these kinases reversed 
the effect of L-165.041, implicating these pathways in 
the observed antiapoptotic effect. It was concluded that 
PPAR β / δ activation might have beneficial effects on acne 
vulgaris by inhibiting the release of lipids associated with 
sebocyte apoptosis  (53) . 
 Skin cancer 
 Non-melanoma skin cancer (NMSC) 
 PPAR β / δ regulates cellular mechanisms that have been 
recognized as pro- or anticancer, such as cell survival, 
migration, and differentiation. Therefore, whether 
PPAR β / δ supports or suppresses tumor formation is 
still being debated  (54, 55) . Similarly, the implication of 
PPAR β / δ in NMSC is much discussed  (54, 56) . 
 The role of PPAR β / δ in cancer development has 
remained elusive, most likely because its promoting or 
repressing effects on the above-mentioned processes are 
fine-tuned in a context-dependent manner, which thus far 
has allowed PPAR β / δ to escape a simplistic view of its func-
tions in tumor biology. Two general models have emerged 
from these studies that attempt to characterize the ambiva-
lent action of PPAR β / δ in tumorigenesis, possibly reflected 
in the variation in genetic defects among tumors. They 
have been presented in some detail recently  (56) . 
 In the first model, PPAR β / δ expression is mediated 
by inflammatory signals through the stress-associated 
protein kinase pathway, in concert with the notion that 
low-grade inflammation is often associated with tumor 
initiation and progression. Alternatively, increased 
PPAR β / δ expression is supported by APC – β -catenin-
dependent signaling, which is enhanced in several 
tumors, especially colorectal carcinomas. An increase in 
PPAR β / δ level is insufficient for the activation of target 
genes, which depends on ligand activation of the recep-
tor. Although endogenous ligands that activate PPAR β / δ 
during tumorigenesis have not yet been identified, they 
are produced and are likely diverse. Once activated, one 
effect of PPAR β / δ is the down-regulation of phosphatase 
and tensin homolog (PTEN), which results in increased 
AKT phosphorylation, which in turn inhibits apopto-
sis and up-regulates vascular endothelial growth factor 
expression, which might promote tumor growth. Fur-
thermore, ANGPTL4, encoded in a previously identified 
PPAR target gene  (57, 58) , has been implicated in cancer 
progression, although evidence that PPARs up-regulate 
ANGPTL4 directly in tumor cells is still lacking  (59) . 
Moreover, at least in colorectal cancer, PPAR β / δ might 
mediate the prostaglandin E2-induced expression of 
ANGPTL4 under hypoxic conditions, which are often 
observed in the tumor environment  (60) . Importantly, 
targeted deletion of PPAR β / δ in colonic epithelial cells 
inhibited azomethane-induced colonic tumorigenesis 
 (61) , and PPAR β / δ is a k-Ras target gene that is up-regu-
lated by the Raf/MEK/ERK pathway in cultured intestinal 
epithelial cells  (62) . However, in another study, germline 
deletion of PPAR β / δ increased azomethane colonic car-
cinogenesis  (63) . Taken together, these two studies might 
indicate paracrine effects of PPAR β / δ . Other factors that 
might have contributed to such contrasting results will 
be discussed below. Interestingly, analysis of human skin 
biopsies of premalignant and malignant skin carcinoma 
documented increased PPAR β / δ expression, which cor-
related with both increased COX-2 expression, which has 
been implicated in skin carcinoma development, and 
increased microvessel density  (64 – 66) . Collectively, these 
studies have implicated PPAR β / δ in skin tumor formation 
and progression. 
 In the second model, activated PPAR β / δ promotes 
terminal epithelial cell differentiation, and therefore cell 
cycle withdrawal. Furthermore, its anti-inflammatory 
action might contribute to decreased tumorigenesis  (56) . 
Several studies, all from the same group, show that loss 
of PPAR β / δ function increases chemically induced skin 
carcinogenesis  (67 – 70) . Along the same line, combining 
ligand activation of PPAR β / δ with inhibition of COX-2 
activity increased the efficacy of preventing chemically 
induced skin tumorigenesis over that of either interven-
tion alone  (70) . This effect of PPAR β / δ was thought to be 
mediated by the inhibition of keratinocyte proliferation, 
mainly through the activity of protein kinase C α . However, 
in transgenic mice that overexpress protein kinase C α , 
7,12-dimethylbenz[ a ]anthracene (DMBA)/TPA treatment 
had no effect on skin tumor susceptibility. Moreover, the 
induction of skin cancer by DMBA/TPA involves different 
molecular mechanisms than skin cancer associated with 
chronic UV exposure, which is largely the more frequent 
form in humans  (71, 72) . Notably, tumor initiation with a 
unique topical dose of the genotoxic carcinogen DMBA 
primarily induces  Ha-Ras -activating mutations, whose 
frequency only reaches 10 – 20 % in human NMSCs  (73 –
 75) . In this context, many upstream signaling pathways 
involved in skin cancer establishment that might be regu-
lated by PPAR β / δ could be blinded by mutations such as 
those affecting Ha-Ras, thereby masking the impact of 
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this nuclear receptor on skin cancer in the DMBA/TPA 
model. 
 In summary, the opposite pro-differentiation and pro-
carcinogenic roles of PPAR β / δ described above may be 
due to different environmental stimuli, possibly impact-
ing ligand production, and/or different genetic contexts, 
which could influence PPAR β / δ activities and functions. 
Furthermore, different mouse genetic models targeting 
the PPAR β / δ DNA binding domain with a complete loss 
of PPAR β / δ function or the transactivating domain that 
might result in a dominant-negative PPAR β / δ were used. 
All of the above-mentioned variables are likely to affect 
the expression pattern of numerous PPAR β / δ target 
genes. Obviously, more work is needed to uncover the 
determinants of the ambivalent role of PPAR β / δ in tumor 
development. 
 Melanoma 
 Similar to NMSC, the incidence of malignant melanoma 
is also steadily increasing  (76) . PPAR β / δ expression has 
been observed in human melanoma biopsies. Low-dose 
pharmacological ligand activation of PPAR β / δ in cultured 
murine and human melanoma cells inhibited cell growth 
 in vitro . At the molecular level, this inhibition is due to the 
direct binding of PPAR β / δ to the Wilms ’ tumor suppres-
sor (WT1) promoter, which represses its activity, and con-
sequently the growth-stimulating effects of WT1 on these 
melanoma cells  (77) . 
 Expert opinion and outlook 
 Exploration of the functions of PPAR β / δ remains of 
highest interest because of its multifaceted roles in major 
cellular and physiological functions. At the molecular 
level, PPAR β / δ operates as a ligand-dependent tran-
scription factor that stimulates or represses gene expres-
sion. The diversity of functions of this receptor, which 
range from the control of basic cellular processes to the 
regulation of complex metabolic functions, represents 
a major challenge for present and future studies  (15) . 
Herein, we have discussed how PPAR β / δ occupies the 
crossroads of multiple functions in skin biology. From 
this discussion, PPAR β / δ emerged as a key factor in skin 
homeostasis and repair. In addition, its implication in 
several skin diseases identifies it as a target to take into 
account in the development of novel therapeutic strate-
gies. The similarity of processes involved in tissue repair 
and tumor development  (78) (Table  1 ), in all of which 
PPAR β / δ is implicated, underscores how many facets 
of PPAR β / δ biology remain hidden. Is the difference, if 
any, between cell proliferation in tissue repair and cell 
proliferation in tumorigenesis situated in parallel with 
the PPAR β / δ repressor and activator activity of these 
processes ? The ambivalent roles of this receptor may 
explain its apparently discordant activities reported in 
the literature. The debate is not closed, and most likely 
reflects the difficulty of accurately describing the highly 
context-specific behaviors of PPAR β / δ , which depend on 
a combination of factors, including the level of recep-
tor expression, co-regulator distribution, activity of 
ligand-producing pathways, and others. In particular, a 
thorough investigation of paracrine signals among the 
PPAR β / δ -dependent effects on carcinogenesis is still 
lacking. Thus, a full understanding of context-specific 
PPAR β / δ activity  – in the skin and elsewhere  – remains 
a burning necessity. Hopefully, the availability of diverse 
new high-throughput technologies allowing global 
analysis of the interactions between the components of 
complex biological systems will assist in a step-by-step 
resolution of today ’ s unsolved problems. 
 Highlights 
 –  PPAR β / δ is involved in the regulation of key 
processes in skin biology in fetal and postnatal life. 
 –  PPAR β / δ promotes keratinocyte and sebocyte 
differentiation and is implicated in hair follicle 
development. 
 –  The inflammatory response to skin wounds enhances 
PPAR β / δ expression and triggers the production of 
PPAR β / δ ligands. Activated PPAR β / δ accelerates 
wound healing. 
 –  During reepithelialization of the wound bed, 
PPAR β / δ enhances keratinocyte survival, directional 
Wound healing Cancer
Controlled proliferation Sustained proliferation
Controlled cell migration (no 
invasion, no metastasis, no 
epithelial-mesenchymal transition)
Invasion metastasis 
(epithelial-mesenchymal 
transition)
Transient resistance to apoptosis Resistance to cell death
Angiogenesis and 
lymphangiogenesis
Angiogenesis and 
lymphangiogenesis
 Table 1   Comparison of the main processes of wound healing and 
cancer that implicate PPAR β / δ . 
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sensing, and migration through cell-autonomous 
mechanisms. 
 –  During wound healing, keratinocyte proliferation 
is attenuated through the PPAR β / δ -dependent 
production of sIL-1Ra by skin fibroblasts, which 
represses the IL-1 signaling that stimulates 
mitogenic cytokine production and secretion by 
these cells. 
 –  PPAR β / δ expression is increased in psoriasis, and 
animal model observations indicate the potential 
usefulness of its topical inhibition to treat this 
disease. 
 –  The role of PPAR β / δ in NMSC is ambivalent, and 
its role in tumor promotion or suppression appears to 
be context-specific and requires further investigation. 
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